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INTRODUCTION: 
 
The oral route of drug administration is the most common 
and preferred method of delivery due to convenience and 
ease of ingestion. From a patient’s perspective, swallowing 
a dosage form is a comfortable and a familiar means of 
taking medication. As a result, patient compliance and 
hence drug treatment is typically more effective with 
orally administered medications as compared with other 
routes of administration
1
. Limited drug absorption 
resulting in poor bioavailability is paramount amongst the 
potential problems that can be encountered when 
delivering an active agent via the oral route. Hence, two 
areas of pharmaceutical research that focus on improving 
the oral bioavailability of active agents include enhancing 
solubility and dissolution rate of poorly water-soluble 
drugs and enhancing permeability of poorly permeable 
drugs
2
. Other methods, such as salt formation, 
complexation with cyclodextrins, solubilization of drugs in 
solvent(s), and particle size reduction have also been 
utilized to improve the dissolution properties of poorly 
water soluble drugs
3,4,5 
.In the Biopharmaceutical 
Classification System (BCS) drugs with low aqueous 
solubility and high membrane permeability are categorized 
as Class II drugs. Therefore, solid dispersion technologies 
are particularly promising for improving the oral 
absorption and bioavailability of BCS Class II drugs
6
. 
SOLID DISPERSION
7
: 
The term solid dispersion refers to a group of solid 
products consisting of at least two different components, 
generally a hydrophilic matrix and a hydrophobic drug. 
The matrix can be either crystalline or amorphous
7
. The 
drug can be dispersed molecularly, in amorphous particles 
(clusters) or in crystalline particles. 
 
Table 1: BCS calssification system
6 
Class Solubility Permeability Example of drugs 
Class I High solubility High permeability Benzapril, Loxoprofen, Sumatriptan etc. 
Class II High solubility Low permeability Valsartan,Nimesulide,Loratadine,Aceclofenac, Glimepiride etc 
Class III Low solubility High permeability Gabapentine, Topiramate, Atropine etc. 
Class IV Low solubility Low  permeability Hydrochlorthiazide,Furosemide,Meloxicam etc. 
 
Table 2: Materials used as carrier for solid dispersion
7 
S. 
N. 
Materials Used As Carriers  Examples 
 
1.  Sugars Dextrose, sucrose, galactose, sorbitol, maltose, xylitol mannitol ,lactose 
2.   Acids  Citric acid, succinic acid 
3.   Polymeric materials Povidone (PVP), polyethylene glycol (PEG), hydroxypropyl methyl cellulose, methyl cellulose, 
hydroxy ethyl cellulose, cyclodextrin, hydroxy propyl cellulose, pectin, galactomannan 
4.   Insoluble or enteric polymer HPMC phthalate, eudragit L100, eudragit S100, Eudragit RL, Eudragit RS 
5.   Surfactants Polyoxyethylene stearate, renex, poloxamer 188, texafor AIP, deoxycholic acid, tweens, spans 
6.   Miscellaneous Pentaerythritol, pentaerythrityl tetraacetate, urea, urethane, hydroxy alkyl xanthins 
 
ABSTRACT 
Solid dispersions have attracted considerable interest as an efficient means of improving the dissolution rate and hence bioavailability 
of a range of hydrotrophic drugs.  Up to 40% of new chemical entities discovered by the pharmaceutical industry today are poorly 
soluble or lipophilic compounds. Solid dispersions of poorly water-soluble drugs with water-soluble carriers reduce the incidence of 
these problems and enhanced dissolution. Solid dispersion is one of the most promising approaches for solubility enhancement. The 
term solid dispersion refers to a group of solid products consisting of at least two different components, generally a hydrophilic matrix 
and a hydrophobic drug. The matrix can be either crystalline or amorphous. As per biopharmaceutical classification system class II 
drugs are with low solubility and high permeability and are the promising candidates for improvement of bioavailability by solid 
dispersion. Some of the practical aspects to be considered for the preparation of solid dispersions, such as selection of carrier, 
molecular arrangement of drugs in solid dispersions are discussed in this article. This article reviews the various preparation 
techniques for solid dispersion, characterization and compiles some of the recent technology transfers. Availability of a wide variety 
of polymers that are themselves poorly soluble or which swell under aqueous conditions suggests that solid dispersions have 
tremendous potential in the area of controlled release dosage forms. 
Keywords: Solid dispersions, solubility, carrier, Biopharmaceutical classification system 
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TYPES OF SOLID DISPERSIONS: 
 Eutectic mixtures: 
      A simple eutectic mixture consists of two compounds 
which are completely miscible in the   liquid state but 
only to a very limited extent in the solid state. It is 
prepared by rapid solidification of fused melt of two 
components that show complete liquid miscibility but 
negligible solid-solid solution
8-11
. 
  Amorphous precipitation in crystalline matrix: 
    This is similar to simple eutectic mixtures but only 
difference is that drug is precipitated     out in an 
amorphous form
12-13 
 Solid solution: Solid solutions are comparable to liquid 
solutions, consisting of just one phase irrespective of 
the number of components. In the case of solid 
solutions, the drug's particle size has been reduced to its 
absolute minimum viz. the molecular dimensions
14
 and 
the dissolution rate is determined by the dissolution rate 
of the carrier. Classified according to their miscibility 
(continuous versus discontinuous solid solutions) or 
second, according to the way in which the solvate 
molecules are distributed in the solvendum 
(substitutional, interstitial or amorphous). 
 Continuous solid solutions: 
     In a continuous solid solution, the components are 
miscible in all proportions. Theoretically, this means 
that the bonding strength between the two components 
is stronger than the bonding strength between the 
molecules of each of the individual components. Solid 
solutions of this type have not been reported in the 
pharmaceutical world till date. 
 Discontinuous solid solutions: 
     In the case of discontinuous solid solutions, the 
solubility of each of the components in the other 
component is limited. Due to practical considerations it 
has been suggested by Goldberg et al.
14
 that the term 
`solid solution' should only be applied when the mutual 
solubility of the two components exceeds 5%. 
  Subsitutional solid dispersions: 
       Substitution is only possible when the size of the 
solute molecules differs by less than 15% or so from 
that of the solvent molecules
15
. Classical solid solutions 
have crystalline structure, in which the solute 
molecules can either substitute for solvent molecules in 
the crystal lattice or fit into the intrsticies between the 
solvent molecule. 
 Interstitial solid solutions: 
      In interstitial solid solutions, the dissolved molecules 
occupy the interstitial spaces between the solvent 
molecules in the crystal lattice. Solute molecule 
diameter should be less than 0.59 times than that of 
solvent molecular diameter.
16 
 Glass solution and suspensions  
      Glass solutions are homogeneous glassy system in 
which solute dissolves in glass carrier. Glass 
suspensions are mixture in which precipitated particles 
are suspended in glass solvent. Lattice energy is much 
lower in glass solution and suspension
13
. 
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Table 3: Types of Solid Dispersion
18 
S.No Solid Dispersion Type Matrix* Drug** Remarks No phases Reference 
1. Eutectics C C The first type of solid  dispersion 
prepared 
2 (Chiou and 
Riegelman, 1971) 
2. Amorphous 
precipitations in 
crystalline matrix 
C A Rarely Encountered 2 (Breitenbach AH, 
2002); 
(Mullins and 
Macek, 1960) 
3. Solid solutions      
A. Continuous Solid 
Solutions 
C M Miscible at all composition, 
never  prepared 
1 (Goldberg et 
al., 1965] 
B Discontinuous solid 
solutions 
 
C M Partially miscible, 2 phases even 
though drug is molecularly 
dispersed 
2 
 
Sekiguchi K and 
Obi N (1961) 
C Substitutional solid 
solutions 
 
C M Molecular diameter of drug 
(solute) differs less than 5% from 
the matrix (solvent) diameter. In 
that case the drug and matrix are 
substitutional. Can be continuous 
or discontinuous. When 
discontinuous: 2 phases even 
though drug is molecularly 
dispersed 
1or 2 (Rastogi and 
Verma,1956); 
(Wilcox et al., 
1964) 
 
D Interstitial solid 
solutions 
 
C M Drug (solute) molecular diameter 
less than 59% of matrix (solvent) 
diameter. Usually limited 
miscibility, discontinuous. 
2 (Chiou and 
Riegelman,1971); 
(Chiou and 
Riegelman, 1969) 
4. Glass suspension A C Particle size of dispersed phase 
dependent on cooling/evaporation 
rate. Obtained after crystallization 
of drug in amorphous matrix 
2 Riegelman, 
1971); 
(Sarkari M et al., 
2002) 
5. Glass suspension A A Particle size of dispersed phase 
dependent on cooling/evaporation 
rate many solid dispersions are of 
this type 
2 Riegelman, 
1971); 
(Sarkari M et al., 
2002) 
6. Glass solution A M Requires miscibility OR solid 
solubility, complex formation or 
upon fast cooling OR evaporation 
during preparation, many (recent) 
examples especially with PVP 
1 Simonelli APet 
al., 1969 
*A: matrix in the amorphous state, C: matrix in the crystalline state 
**: A: drug dispersed as amorphous clusters in the matrix, C: drug dispersed as crystalline particles in the matrix, M: drug molecularly dispersed 
throughout the matrix 
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SELECTION OF A CARRIER: 
A carrier should meet the following criteria to be suitable 
for increasing the dissolution rate of a drug.
3,7,17,19 
 Freely water-soluble with intrinsic rapid dissolution 
properties. 
 Non-toxic and pharmacologically inert. 
 Heat stable with a low melting point for the melt 
method. 
 Soluble in a variety of solvents and pass through a 
vitreous state upon solvent evaporation for the 
solvent method. 
 Able to preferably increase the aqueous solubility of 
the drug. 
 Chemically compatible with the drug and not form a 
strongly bonded complex with the drug. 
FIRST GENERATION CARRIERS: 
    Example: Crystalline carriers: Urea, Sugars, Organic 
acids
20
. 
SECOND GENERATION CARRIERS:  
Example: Fully synthetic polymers include povidone 
(PVP), polyethyleneglycols (PEG) and 
polymethacrylates
19
.Natural product based polymers are 
mainly composed by cellulose derivatives, such as 
hydroxypropylmethylcellulose (HPMC), ethylcellulose or 
hydroxypropylcellulose or starch derivates, like 
cyclodextrins
21
. 
THIRD GENERATION CARRIERS: 
Example: Surface active self-emulsifying carriers: 
Poloxamer 408, Tween 80, and Gelucire 44/141  
 
Figure 6: Classification of solid dispersion 
SELECTION OF SOLVENTS: 
Solvent to be included for the formulation of solid 
dispersion should have the following criteria: 
 Both drug and carrier must be dissolved. 
 Toxic solvents to be avoided due to the risk of residual 
levels after preparation e.g. chloroform and 
dichloromethane
22
. 
  Ethanol can be used as alternative as it is less toxic. 
  Water based systems are preferred. 
 Surfactants are used to create carrier drug solutions but 
as they can reduce glass transition temperature, so care 
must be taken in to consideration. 
Table 4: List of Solvents Used In Solid Dispersion
22 
S.NO SOLVENT MELTING POINT (°C) BOILING POINT (°C) 
1 Water 0 100 
2 Methanol -93.9 65 
3 Ethanol -117 78.5 
4 Acetic acid 17 118 
5 1-propanol -85 97.4 
6 2-propanol -127 82.4 
7 Chloroform -63 62 
8 DMSO 19 189 
 
ADVANTAGES OF SOLID DISPERSION: 
Particles with Reduced Particle Size 
Molecular dispersions, as solid dispersions, represent the 
last state on particle size reduction, and after carrier 
dissolution the drug is molecularly dispersed in the 
dissolution medium. Solid dispersions apply this principle 
to drug release by creating a mixture of a poorly water 
soluble drug and highly soluble carriers. A high surface 
area is formed, resulting in an increased dissolution rate 
and, consequently, improved bioavailability
23
. 
Particles with Improved Wettability 
Carriers with surface activity, such as cholic acid and bile 
salts. When used, can significantly \increase the wettability 
property of drug. Even carriers without any surface 
activity, such as urea, improved drug wettability. Carriers 
can influence the drug dissolution profile by direct 
dissolution or co-solvent effects. 
Particles with Higher Porosity 
Particles in solid dispersions have been found to have a 
higher degree of porosity. The increase in porosity also 
depends on the carrier properties; for instance, solid 
dispersions containing linear polymers produce larger and 
more porous particles than those containing reticular 
polymers and, therefore, result in a higher dissolution rate. 
The increased porosity of solid dispersion particles also 
hastens the drug release profile. 
Drugs in Amorphous State 
Poorly water soluble crystalline drugs, when in the 
amorphous state tend to have higher solubility. The 
enhancement of drug release can  usually be achieved 
using the drug in itsamorphous state, because no energy is 
required to break up the crystal lattice during the 
dissolution process For drugs with low crystal energy (low 
melting temperature or heat of fusion), the amorphous 
composition is primarily dictated by the difference in 
melting temperature between drug and carrier
24
. For drugs 
with high crystal energy, higher amorphous compositions 
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can be obtained by choosing carriers, which exhibit 
specific interactions with them. 
DISADVANTAGES OF SOLID DISPERSION: 
The major disadvantages of solid dispersion are related to 
their instability. Several systems have shown changes in 
crystallinity and a decrease in dissolution rate with aging. 
The crystallization of ritonavir from the supersaturated 
solution in a solid dispersion system was responsible for 
the withdrawal of the ritonavir capsule (Norvir, \Abboft) 
from the market
25
.  
Moisture and temperature have more of a deteriorating 
effect on solid dispersions than on physical mixtures. 
Some solid dispersion may not lend them to easy handling 
because of tackiness. 
APPLICATIONS OF SOLID DISPERSION IN 
PHARMACEUTICAL FIELD: 
Apart from absorption enhancement, the solid dispersion 
technique may have numerous pharmaceutical 
applications, which should be further explored. It is 
possible that such a technique be used: 
 To obtain a homogeneous distribution of a small 
amount of drug in solid state. 
 To stabilize the unstable drug26. 
 To dispense liquid (up to 10%) or gaseous compounds 
in a solid dosage. 
 To formulate a fast release primary dose in a sustained 
released dosage form. 
 To formulate sustained release regimen of soluble 
drugs by using poorly soluble or insoluble carriers. 
 To reduce pre systemic inactivation of drugs 
likemorphine and progesterone
27
. 
 Polymorphs in a given system can be converted into 
isomorphous, solid solution, eutectic or molecular 
addition compounds
28
.  
MECHANISM OF BIOAVAILABILITY 
ENHANCEMENT: 
The enhancement in dissolution rate because of solid 
dispersion formation, relative to pure drug, varies from as 
high as 400 fold to less than two fold
29
. The increase in 
dissolution rate can be attributed to myriad factors and it is 
very difficult to show experimentally that any one 
particular factor is more important than the other. Solid 
dispersions increase the dissolution rate of poorly 
watersoluble drugs by one of the following mechanisms
30
 . 
 Reduction in particle size  
 Improvement in wettability and dispersibility 
 Changing crystalline form of drug to amorphous form  
 Reduction in aggregation and agglomeration of drug 
particles. 
POLYMERS USED IN SOLID DISPERSIONS: 
Polyethylene Glycol (PEG): 
The term polyethylene glycol refers to compounds that are 
obtained by reacting ethylene glycol with ethylene oxide. 
PEGs whose molecular weight is above 300000 are 
commonly termed as polyethylene oxides30
31 
Phospholipids: 
The complexity of glycerides advances by modification of 
the terminal hydroxyl with phosphate linked head groups 
to form phospholipids, common phospholipid head groups 
include choline, ethanolamine, serine, inositol and inositol 
phosphate, and glycerol esters
32
. As with the triglycerides, 
numerous species are possible by various combinations of 
different head groups and fatty acyl substitution at the first 
and second positions of the glycerol backbone, fluidity 
differences are evident as a function of the gel to liquid 
crystalline transition temperatures. Solubility of 
phospholipids is intimately linked to the confirmation of 
the aggregate material rather than strictly a chemical 
function of the molecule. Monoacyl phospholipids, which 
tend to form micelles, are usually more readily soluble in 
aqueous solutions
31 
Polyvinyl Pyrrolidone (PVP): 
PVP has a molecular weight ranging from 10000 to 
700000. It is soluble in solvents like water, ethanol, 
chloroform and isopropyl alcohol. PVP is not suitablefor 
preparation of solid dispersions prepared by melt method 
because of its melt at a very high temperature above 275, 
where it becomes decomposed.  
Effect of PVP Molecular Weight: 
The effect of molecular weight of PVP on the rate of 
dissolution of a drug is more consistent  than for PEG. An 
increase in molecular weight of PVP will decrease the 
dissolution rate of most drugs.
32
 An increase in viscosity of 
PVP solution due to an increase in molecular weight 
decreases diffusion of drug molecules from the surface of 
viscous material into the dissolution medium, lower 
molecular weight PVP has a short swelling time prior to 
dissolution resulting in an increase in dissolution n rate of 
the polymer and drug. 
Cyclodextrins: 
Cyclodextrins are primarily used to enhance solubility, 
chemical protection, taste masking \and improved handling 
by the conversion of liquids into solids by entrapment
33,34
.  
Advantages of Cyclodextrins: 
 Increasing the stability of the drug  
 Release profile during gastrointestinal  
 transit through modification of drug  
 Release site and time profile35.  
 Decreasing local tissue irritation.  
 Masking unpleasant taste.  
METHODS OF PREPARATION OF SOLID 
DISPERSION: 
Melting method:
 
 
The melting or fusion method, first proposed by Sekiguchi 
and Obi involves the preparation of physical mixture of a 
drug and a water-soluble carrier and heating it directly 
until it melted. The melted mixture is then solidified 
rapidly in an ice-bath under vigorous stirring. The final 
solid mass is crushed, pulverized and sieved. 
Appropriately this has undergone many modifications in 
pouring the homogenous melt in the form of a thin layer 
onto a ferrite plate or a stainless steel plate and cooled by 
flowing air or water on the opposite side of the plate. In 
addition, a super-saturation of a solute or drug in a system 
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can often be obtained by quenching the melt rapidly from a 
high temperature
36
. Under such conditions, the solute 
molecule is arrested in the solvent matrix by the 
instantaneous solidification process. The quenching 
technique gives a much finer dispersion of crystallites 
when used for simple eutectic mixtures. 
Solvent method: 
In this method, the physical mixture of the drug and carrier 
is dissolved in a common solvent, which is evaporated 
until a clear, solvent free film is left. The film is further 
dried to constant weight. The main advantage of the 
solvent method is thermal decomposition of drugs or 
carriers can be prevented because of the relatively low 
temperatures required for the evaporation of organic 
solvents
37
. 
However, some disadvantages are associated with this 
method such as 
 The higher cost of preparation. 
 The difficulty in completely removing liquid solvent. 
 The possible adverse effect of traces of the solvent on 
the chemical stability          
 The selection of a common volatile solvent. 
 The difficulty of reproducing crystal form. 
  In addition, a super saturation of the solute in the solid 
system cannot be attained  except in a system showing 
highly viscous properties. 
Melting solvent method (melt evaporation): 
It involves preparation of solid dispersions by dissolving 
the drug in a suitable liquid solvent and then incorporating 
the solution directly into the melt of polyethylene glycol, 
which is then evaporated until a clear, solvent free film is 
left. The film is further dried to constant weight. The 5 –
10% (w/w) of liquid compounds can be incorporated into 
polyethylene glycol6000 without significant loss of its 
solid property
37
. It is possible that the selected solvent or 
dissolved drug may not be miscible with the melt of the 
polyethylene glycol. Also the liquid solvent used may 
affect the polymorphic form of the drug, which precipitates 
as the solid dispersion. This technique possesses unique 
advantages of both the fusion and solvent evaporation 
methods. From a practical standpoint, it is only limited to 
drugs with a low therapeutic dose e.g. below 50 mg. 
Melt extrusion method: 
The drug/carrier mix is typically processed with a twin-
screw extruder. The drug/carrier mix is simultaneously 
melted, homogenized and then extruded and shaped as 
tablets, granules, pellets, sheets, sticks or powder. The 
intermediates can then be further processed into 
conventional tablets. An important advantage of the hot 
melt extrusion method is that the drug/carrier mix is only 
subjected to an elevated temperature for about 1 min, 
which enables drugs that are somewhat thermo labile to be 
processed.Solid dispersion by this method is composed of   
active ingredient and carrier, and prepare by hot-stage 
extrusion using a co-rotating twin-screw extruder. The 
concentration of drug in the dispersions is always 40% 
(w/w). The screw-configuration consist of two mixing 
zones and three transport zones distribute over the entire 
barrel length, the feeding rate is fix at 1 kg/h and the screw 
rate is set at 300 rpm. The five temperature zones are set at 
100, 130, 170, 180, and 185C from feeder to die. The 
extrudates are collect after cooling at ambient temperature 
on a conveyer belt. Samples are milled for 1 min with a 
laboratory-cutting mill   and sieve to exclude particles 
>355µm. 
Lyophilisation Technique: 
Freeze-drying involves transfer of heat and mass to and 
from the product under preparation
37
. This technique was 
proposed as an alternative technique to solvent 
evaporation. Lyophilisation has been thought of a 
molecular mixing technique where the drug and carrier are 
co dissolved in a common solvent, frozen and sublimed to 
obtain a lyophilized molecular dispersion. 
Melt Agglomeration Process : 
This technique has been used to prepare SD wherein the 
binder acts as a carrier. In addition, SD(s) are prepared 
either by heating binder, drug and excipient to a 
temperature above the melting point of the binder (melt- in 
procedure) or by spraying a dispersion of drug in molten 
binder on the heated excipient (spray-on procedure) by 
using a high shear mixer
38
. A rotary processor has been 
shown to be alternative equipment for melt agglomeration. 
The rotary processor might be preferable to the high melt 
agglomeration because it is easier to control the 
temperature and because a higher binder content can be 
incorporated in the agglomerates
19
. The effect of binder 
type, method of manufacturing and particle size are critical 
parameters in preparation of SD(s) by melt agglomeration. 
Since these parameters result in variations in dissolution 
rates, mechanism of agglomerate formation and growth, 
agglomerate size, agglomerate size distribution and 
densification of agglomerates. It has been investigated that 
the melt in procedure gives a higher dissolution rates than 
the spray-on procedure with PEG 3000, poloxamer 188 
and gelucire 50/13 attributed to immersion mechanism of 
agglomerate formation and growth. In addition the melt in 
procedure also results in homogenous distribution of drug 
in agglomerate. Larger particles results in densification of 
agglomerates while fine particle cause complete adhesion 
to the mass to bowl shortly after melting attributed to 
distribution and coalescence of the fine particles. 
The use of surfactant : 
The utility of the surfactant systems in solubilization is 
well known. Adsorption of surfactant on solid surface can 
modify their hydrophobisity, surface charge, and other key 
properties that govern interfacial processes such as 
flocculation/dispersion, floatation, wetting, solubilization, 
detergency, enhanced oil recovery and corrosion 
inhibition. Surfactants have also been reported to cause 
solvation/plasticization, manifesting in reduction of 
melting the active pharmaceutical ingredients, glass 
transition temperature and the combined glass transition 
temperature of solid dispersions. Because of these unique 
properties, surfactants have attracted the attention of 
investigators for preparation of solid dispersions.. 
Electrospinning : 
Electrospinning is a process in which solid fibers are 
produced from a polymeric fluid stream solution or melt 
delivered through a millimeter-scale nozzle
38
. This process 
involves the application of a strong electrostatic field over 
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a conductive capillary attaching to a reservoir containing a 
polymer solution or melt and a conductive collection screen. 
Upon increasing the electrostatic field strength up to but not 
exceeding a critical value, charge species accumulated on the 
surface of a pendant drop destabilize the hemispherical shape 
into a conical shape (commonly known as Taylor s cone). 
Beyond the critical value, a charged polymer jet is ejected 
from the apex of the cone (as a way of relieving the charge 
built-up on the surface of the pendant drop). The ejected 
charged jet is then carried to the collection screen via the 
electrostatic force. The Coulombic repulsion force is 
responsible for the thinning of the charged jet during its 
trajectory to the collection screen. The thinning down of the 
charged jet is limited by the viscosity increase, as the charged 
jet is dried 
39
. This technique has tremendous potential for the 
preparation of nanofibres and controlling the release of 
biomedicine, as it is simplest,the cheapest 
25 
this technique can 
be utilized for the preparation of solid dispersions in future. 
Super Critical Fluid (Scf) Technology: 
This technology has been introduced in the late 1980s and 
early 1990s, and experimental proofs of concept are abundant 
in the scientific literature for a plethora of model compounds 
from very different areas such as drugs and pharmaceutical 
compounds, polymers and biopolymers, explosives and 
energy materials, superconductors and catalyst precursor’s 
dyes and biomolecules such as proteins and peptides. From 
the very beginning of supercritical fluid particle generation 
research, the formation of biocompatible polymer and drug-
loaded biopolymer micro-particles for pharmaceutical 
applications has been studied intensively by a number of 
researcher groups
38 
CFs either as solvent: rapid expansion 
from supercritical solution (RESS) or antisolvent: gas 
antisolvent (GAS), supercritical antisolvent (SAS), solution 
enhanced dispersion by supercritical fluids (SEDS) and/or 
dispersing fluid: GAS, SEDS, particles from gas-saturated 
solution (PGSS). Conventional methods, i.e. Spray drying, 
solvent evaporation and hot melt method often result in low 
yield, high residual solvent content or thermal degradation of 
the active substance
39
 the supercritical fluid antisolvent 
techniques, carbon dioxide is used as an antisolvent for the 
solute but as a solvent with respect to the organic solvent. 
Different acronyms were used by various authors to denote 
micronization processes: aerosol solvent extraction system 
(ASES), precipitation with a compressed fluid antisolvent 
(PCA), gas anti-solvent (GAS), solution enhanced dispersion 
by supercritical fluids (SEDS) and supercritical anti-solvent 
(SAS). The SAS process involves the spraying of the solution 
composed of the solute and of the organic solvent into a 
continuous supercritical phase flowing cocurrently 
38 
use of 
supercritical carbon dioxide is advantageous as it is much 
easier to remove from the polymeric materials when the 
process is complete, even though a small amount of carbon 
dioxide remains trapped inside the polymer; it poses no 
danger to the patient. In addition the ability of carbon dioxide 
to plasticize and swell polymers can also be exploited and the 
process can be carried out near room temperature 
39 
Moreover, 
supercritical fluids are used to lower the temperature of melt 
dispersion process by reducing the melting temperature of 
dispersed active agent. The reason for this depression is the 
solubility of the lighter component (dense gas) in the forming 
phase (heavier component)
40
. 
MARKETED PRODUCTS: 
 Gris-PEG, a griseofulvin-PEG fusion method solid 
dispersion, was manufactured initially by  
 Dorsey / Sandoz and reached the market in the mid- 
1970s.Gris-PEG was developed as tablet product, and this 
led to two USP monographs for griseofulvin tablets. 
Griseofulvin solid dispersion.tablets are currently 
marketed by a number of manufacturers and contain corn 
starch, lactose, magnesium stearate, PEG, and sodium 
lauryl sulfate as inactive ingredients
41
. 
 Cesamet, a nabilone-PVP solvent method solid dispersion 
manufactured by Eli Lilly and Co. has been marketed 
internationally since 1982. Eli Lilly discontinued 
marketing Cesamet contains PVP and corn starch as 
inactive ingredients and is presented as a capsule 
product
42
. 
 Solid dispersion formulation of Troglitazone (Rezulin) is 
marketed by Parke-Davis. 
 Solid Solutions of lopinavir and ritonavir in 
polyvinylpyrrolidone-vinyl acetate. copolymer 
successfully enabled a reformulation of "Kaletra" ( Abbott 
Laboratories, Abbott Park, IL). In addition to reducing the 
dosage burden from six softgel capsules to four tablets, 
tablets made with the solid solutions eliminate the need for 
refrigeration. 
 "Sporanox" (Janssen Pharmaceutica, Titusville, NJ) is a 
solid dispersion of itraconazole in hypromellose that has 
been layered onto sugar spheres. 
 The most recently approved product is the nonnucleoside 
reverse transcriptase inhibitor"Intelence" ( Tibotec, 
Yardley, PA), an amorphous, spray-dried solid dispersion 
of etravirine, hypromellose, and microcrystalline 
cellulose. 
CHARACTERIZATION OF SOLID DISPERSION: 
Many methods are available that can contribute information 
regarding the physical nature of solid dispersion system. A 
combination of two or more methods is required to study its 
complete picture
43
.  
 Thermal analysis.  
 Spectroscopic method.  
 X-ray diffraction method.  
 Dissolution rate method.  
 Microscopic method.  
 Thermodynamic method.  
 Modulated temperature differential scanning calorimetry  
 Environmental scanning electron microscopy  
 Dissolution testing  
RECENT ADVANCES AND FUTURE TRENDS: 
Solid dispersion has great potential both for increasing the 
bioavailability of drug and developing controlled release 
preparations. Thus, to solve bioavailability issues with respect 
to poorly water-soluble drugs, solid dispersion technology has 
grown rapidly. The dosage form can be developed and 
prepared using small amounts of drugs substances in early 
stages of the drug development process, the system might 
have an advantage over such other commonly used 
bioavailability enhancement techniques as micronization of 
drugs and soft gelatin encapsulation.  
CONCLUSION: 
The enhancement of oral bioavailability of poorly water 
soluble drugs remains one of the most challenging aspects of 
drug development. Dissolution of drug is the rate determining 
step for oral absorption of drugs, which can subsequently 
affect the in vivo absorption of drug. Because of solubility 
problem of many drugs the bioavailability of these gets 
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affected and hence solubility enhancement becomes 
necessary. Solid dispersions are one of the most attractive 
processes to improve drug’s poor water solubility. Various 
solubility enhancers like water-soluble carriers, co solvents, 
surfactants and superdisintegrants via solid dispersion 
approach (fusion method and solvent evaporation method) 
aids in solubility enhancement. These significantly help to 
improve the bioavailability and bioequivalence.
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